- Open Access
Phosphaturic mesenchymal tumour of the sinonasal area: case report and review of the literature
© Komínek et al; licensee BioMed Central Ltd. 2011
- Received: 11 December 2010
- Accepted: 16 March 2011
- Published: 16 March 2011
Oncogenous osteomalacia (OOM), which is also known as tumour-induced osteomalacia, is a rare condition associated with a neoplasm and a related systemic bone demineralization caused by renal phosphate wasting. OOM usually occurs in association with a variety of different mesenchymal tumours, and they were categorized into four distinct morphological patterns which they termed "phosphaturic mesenchymal tumour". Of its 4 histopathological subtypes, the mixed connective tissue variant is most commonly observed. Only 10% of cases appear in the head and neck regions and moreover, only 5 previously published tumors were localized in the sinonasal area. The authors describe a case of a man with a PMT originating from the frontoethmoidal region.
A 53-year-old man was referred to our ORL clinic due to a presence of a mass at the nasal root having been growing asymptomatically for 1 year. CT scans demonstrated a large (25 × 20 × 35 mm) bilateral frontoethmoidal mass with destruction of nasal bones. The tumor did not appear to invade to the anterior skull base. A selective angiography revealed a moderate hypervascularization of the tumour during early and late arterial phases. The tumour was removed from the external approach and the definitive histopathological diagnosis was a phospaturic mesenchymal tumor. Dual energy X-ray absorptiometry revealed a slight osteopenia of the first and second lumbar vertebrae and neck of the thigh bone. The serum and urinary levels of both calcium and anorganic phosphate were within normal limits. The patient is doing well three years after the operation, and the serum and urine levels of calcium and phosphate remain well within normal limits.
PMT is rare in the sinonasal region, it can be rarely observed without the signs of osteomalacia.
- phosphaturic tumour
- oncogenous osteomalacia
Oncogenous osteomalacia (OOM), which is also known as tumour-induced osteomalacia, is a rare condition associated with a neoplasm and a related systemic bone demineralization caused by renal phosphate wasting [1, 2]. In 1947, unaware of the causative relation between phosphate wasting and this neoplasm, McCance published the first case . OOM usually occurs in association with a variety of different tumour types, frequently very small, a fact which makes their discovery difficult [2–4]. Most published cases were presented by various soft tissue, bone neoplasms, and pseudotumors [4, 5]. In 1987 Weidner and Santa Cruz revealed that many of these mesenchymal tumours were histologically polymorphous, and they were categorized into four distinct morphological patterns which they termed "phosphaturic mesenchymal tumour" (PMT), comprising four subtypes . The most common one was a mixed connective tissue variant (MCT), composed of primitive mesenchymal cells. Quite recently, Folpe and colleagues have reviewed 32 personal and 109 reported mesenchymal OO-associated tumors, the latter representing the majority of all published (English literature) cases . 102 out of the total of 141 various mesenchymal tumors were reclassified as true or probable phosphaturic mesenchymal tumor mixed connective tissue variant (PMTMCT) and the above-mentioned three other variants of PMT. Only 5 previously published tumors were localized in the sinonasal area .
Because of its scarcity, most ENT surgeons remain oblivious to the existence of PMTMCT. Here, the case of a 53-year-old man with a PMTMCT, originating bilaterally from the frontoethmoidal region, is described.
The course, thereafter, was uneventful, and two years after the operation the patient is doing well; there is no evidence of the disease in either endoscopic or CT examinations, and the serum and urine levels of calcium and phosphate remain well within normal limits.
Phosphaturic mesenchymal tumour (PMT) is representative of a very rare group of neoplasms, usually benign [2, 5, 6]. PMT with the mixed connective tissue variant (PMTMCT) is the most commonly observed, while the remaining minority consists of the three other histopathological subtypes (an osteoblastoma-like tumour, a non-ossifying fibroma-like tumour and an ossifying fibroma-like tumour) [3, 4]. They are distinguished from other mesenchymal tumours by the expression of a number of gene products, which are related to bone matrix formation, mineralisation and mineral ion transport [3, 7].
A review of sinonasal PMT MCT
Follow-up interval/tumour/signs of OO
F, 39 y
max. sinus, infratemporal fossa invasion, right
F, 69 y
max. and frontal sinus, ethmoids, intracranial invasion, right
died of tumor-related reasons
F, 54 y
F, 38 y
max. sinus, ethmoids, nasal cavity, orbital floor invasion, left
radiotherapy part. surg. removal
18 mo/not indicated/present
F, 53 y
nasal cavity, ethmoids, right
M, 53 y
frontal sinus, ethmoids, nasal cavity billat
24 mo/no evidence of tumor/primarily not present
The mechanism of the tumour-induced osteomalacia remained unclear for many years but all the evidence pointed to a circulating phosphaturic agent [2, 3, 7, 11]. Recently, it has been demonstrated that some OOM-associated tumours, including PMTMCT, over express fibroblast growth factor FGF-23, a protein, which inhibits renal phosphate reabsorption by a mechanism distinct from that of other known phosphate homeostasis hormones [2, 3, 11]. The precise role of FGF-23 in the pathogenesis of OOM is uncertain, but most FGFs are potent stimulators of angiogenesis in vitro and in vivo .
There were neither clinical nor laboratory signs of osteomalacia in our patient with the tumour, which met unambiguously all histopathological criteria for a PMTMCT. Similarly, Folpe et al in their study revealed 3 cases of PMCMCT without a known history of phosphaturia, which they had considered a non-phosphaturic variant of this histopathologic entity . They speculated that in such cases the tumour either secreted inactive or insufficient FGF-23, or even none whatsoever. Another possible explanation could be the patient's capacity to compensate for the increased secretion of this factor in another manner . Unfortunately, since the FGF-23 antibody is not commercially available, we failed to test the above-described tumour for that factor. In this respect, our case was not contributory. For establishing the histopathological diagnosis of a PMTMCT, FGF-23 immunohistochemistry is not crucial.
PMTMCT is basically a benign lesion, histologically malignant, metastasizing variants of which happen to occur extremely rarely [5, 7]. Nonetheless, infiltration and invasion of surrounding tissues are very frequent features of this otherwise benign-appearing PMTMCT [3, 5].
In general, a reasonable treatment protocol for PMT MTC is a complete surgical removal, which dramatically resolves the tumour-associated osteomalacia (known for its resistance to conservative therapy). Owing to its local invasiveness, the lesion should be removed using wide margins of resection [2, 5–7]. Remnants of the tumour may be inadvertently left behind, threatening the patient with serious local and systemic complications resulting from continuous growth and renal phosphate wasting, respectively . A postoperative laboratory and radiological follow-up is thus necessary .
In most patients with oncogenous osteomalacia, the causative tumour is a PMTMCT. About 5% of all these lesions originate in the frontoethmoidal area. Here, the tumour may easily go unrecognized until a thorough battery of CT scans is performed. Local invasion is a characteristic feature of benign PMTMCT, requiring wide-margin resection. Given the spatial limitations imposed by surrounding anatomical structures, residual tumour may be left behind in that area, making careful follow-ups an absolute necessity.
- McCance RA: Osteomalacia with Looser's nodes (Milkman's syndrome) due to a raised resistance to Vitamin D acquired about the age of 15 years. Quart J Med. 1947, 16: 33-46.PubMedGoogle Scholar
- Koriyama N, Nishimoto K, Kodama T, et al: Oncogenic osteomalacia in a case with maxillary sinus mesenchymal tumor. J Med Sci. 2006, 332 (4): 141-147.Google Scholar
- Williams K, Flanagan A, Folpe A, et al: Lymphatic vessels are present in phosphaturic mesenchymal tumours. Wirchows Arch. 2007, 451: 871-875. 10.1007/s00428-007-0471-y.View ArticleGoogle Scholar
- Weidner N, Santa Cruz D: Phosphaturic mesenchymal tumours. A polymorphous group causing osteomalacia or rickets. Cancer. 1987, 59: 1442-1454. 10.1002/1097-0142(19870415)59:8<1442::AID-CNCR2820590810>3.0.CO;2-Q.View ArticlePubMedGoogle Scholar
- Folpe AL, Fanburg-Smith JC, Billlings SD, et al: Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity, the "phosphaturic mesenchymal tumor, mixed connective tissue variant": An analysis of 32 cases and a comprehensive review of the literature. Am J Surg. 2004, 28: 1-30. 10.1097/00000478-200401000-00001.Google Scholar
- Gonzales-Compta X, Manos-Pujol M, Foglia-Fernandez M, et al: Oncogenic osteomalacia: case report and review of head and neck associated tumours. J Laryngol Otol. 1998, 112: 389-392.Google Scholar
- Yun KI, Kim DH, Pyo SW: A Phosphaturic mesenchymal tumor of the floor of the mouth with oncognic osteomalacia: report of a case. J Oral Maxillofac Surg. 2009, 67: 402-405. 10.1016/j.joms.2008.01.007.View ArticlePubMedGoogle Scholar
- Linsey M, Smith W, Yamauchi H, Bernstein L: Nasopharyngeal angiofibroma presenting as adult osteomalacia: case report and review of the literature. Laryngoscope. 1983, 93: 1328-1331.PubMedGoogle Scholar
- Papotti M, Foschini MP, Isaia G, Rizzi G, Betts CM, Eusebi V: Hypophosphatemic oncogenic osteomalacia: report of three new cases. Tumori. 1988, 74: 599-607.PubMedGoogle Scholar
- Kawai Y, Morimoto S, Sakaguchi K, Yoshino H, Yutsui T, Hirota S, et al: Oncogenic osteomalacia secondary to nasal tumor with decreased urinary excertion of cAMP. J Bone Miner Metab. 2001, 19: 61-64. 10.1007/s007740170062.View ArticlePubMedGoogle Scholar
- Shimada T, Mizutani S, Muto T, et al: Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Ntl Acad Sci USA. 2001, 98: 6500-6505. 10.1073/pnas.101545198.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.